美国华盛顿大学Kelly R. Stevens小组研究开发出了生物打印平台并行筛选工程微组织在体内。相关论文于2025年3月31日发表在《细胞—干细胞》杂志上。

该团队引入了一种“即插即用”平台，称为并行宿主定位，用于筛选体内组织（PHAST）。PHAST可以在单个3D打印设备中对43个三维显微组织进行并行体内测试。使用PHAST，研究小组筛选具有不同细胞和材料成分的微组织形成，并确定支持血管移植物-宿主融合和体内工程肝组织功能的配方。他们的研究表明，为了获得最佳的体内性能，工程组织中应该包含的细胞群是依赖于物质的。PHAST可以加速临床再生和修复人体组织疗法的发展。

研究人员表示，人体工程组织在治疗性组织再生和修复方面具有很大的前景。然而，由于工程组织配方的复杂性（通常由不同的细胞群和材料元素组成）以及体内实验的单调性，这些技术的发展往往停滞在体内研究阶段。

附：英文原文

Title: Bioprinted platform for parallelized screening of engineered microtissues in vivo

Author: Colleen E. O’Connor, Fan Zhang, Anna Neufeld, Olivia Prado, Susana P. Simmonds, Chelsea L. Fortin, Fredrik Johansson, Jonathan Mene, Sarah H. Saxton, Irina Kopyeva, Nicole E. Gregorio, Zachary James, Cole A. DeForest, Elizabeth C. Wayne, Daniela M. Witten, Kelly R. Stevens

Issue&Volume: 2025-03-31

Abstract: Human engineered tissues hold great promise for therapeutic tissue regeneration and repair. Yet, development of these technologies often stalls at the stage of in vivo studies due to the complexity of engineered tissue formulations, which are often composed of diverse cell populations and material elements, along with the tedious nature of in vivo experiments. We introduce a “plug and play” platform called parallelized host apposition for screening tissues in vivo (PHAST). PHAST enables parallelized in vivo testing of 43 three-dimensional microtissues in a single 3D-printed device. Using PHAST, we screen microtissue formations with varying cellular and material components and identify formulations that support vascular graft-host inosculation and engineered liver tissue function in vivo. Our studies reveal that the cellular population(s) that should be included in engineered tissues for optimal in vivo performance is material dependent. PHAST could thus accelerate development of human tissue therapies for clinical regeneration and repair.

DOI: 10.1016/j.stem.2025.03.002

Source: https://www.cell.com/cell-stem-cell/abstract/S1934-5909(25)00092-X